Metabolomics

Dataset Information

0

A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy(Part 2)


ABSTRACT: Chimeric antigen receptor (CAR)-T cell-based immunotherapy for cancer and immunological diseases has made great strides, but it still faces multiple hurdles. Finding the right molecular targets to engineer T cells toward a desired function has broad implications for the armamentarium of T cell-centered therapies. Here, we developed a dead-guide RNA (dgRNA)-based CRISPR activation screen in primary CD8+ T cells, and identified gain-of-function (GOF) targets for CAR-T engineering. Targeted knock-in or overexpression of a lead target, PRODH2, enhanced CAR-T-based killing and in vivo efficacy in multiple cancer models. Transcriptomics and metabolomics in CAR-T cells revealed that augmenting PRODH2 expression re-shaped broad and distinct gene expression and metabolic programs. Mitochondrial, metabolic and immunological analyses showed that PRODH2 engineering enhances the metabolic and immune functions of CAR-T cells against cancer. Together these findings provide a system for identification of GOF immune boosters, and demonstrate PRODH2 as a target to enhance CAR-T efficacy.

ORGANISM(S): Human Homo Sapiens

TISSUE(S): Cultured Cells

DISEASE(S): Cancer

SUBMITTER: Lupeng Ye  

PROVIDER: ST002084 | MetabolomicsWorkbench | Mon Feb 14 00:00:00 GMT 2022

REPOSITORIES: MetabolomicsWorkbench

Similar Datasets

2022-02-12 | ST002085 | MetabolomicsWorkbench
2022-12-13 | GSE216286 | GEO
2021-12-01 | GSE164425 | GEO
2021-12-01 | GSE164500 | GEO
2017-10-24 | PXD007552 | Pride
2021-09-01 | BIOMD0000001024 | BioModels
2021-09-01 | BIOMD0000001025 | BioModels
2023-05-18 | GSE225185 | GEO
2023-05-18 | GSE225184 | GEO
2022-12-09 | GSE201997 | GEO